Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy REGENXBIO stock | $35.98

Learn how to easily invest in REGENXBIO stock.

REGENXBIO Inc is a biotechnology business based in the US. REGENXBIO shares (RGNX) are listed on the NASDAQ and all prices are listed in US Dollars. REGENXBIO employs 306 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in REGENXBIO

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RGNX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.


Use our graph to track the performance of RGNX stocks over time.

REGENXBIO shares at a glance

Information last updated 2021-10-25.
Latest market close$35.98
52-week range$27.15 - $50.26
50-day moving average $38.23
200-day moving average $35.77
Wall St. target price$63.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.65

Buy REGENXBIO shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy REGENXBIO stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

REGENXBIO price performance over time

Historical closes compared with the close of $35.98 from 2021-10-26

1 week (2021-10-21) 2.71%
1 month (2021-09-28) -17.27%
3 months (2021-07-28) 5.82%
6 months (2021-04-28) 0.50%
1 year (2020-10-27) 20.94%
2 years (2019-10-25) -11.34%
3 years (2018-10-26) 60.92
5 years (2016-10-27) 120.74%

Is REGENXBIO under- or over-valued?

Valuing REGENXBIO stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of REGENXBIO's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.


REGENXBIO's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.26. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into REGENXBIO's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

REGENXBIO financials

Revenue TTM $161.3 million
Gross profit TTM $-47,441,000
Return on assets TTM -13.22%
Return on equity TTM -32.09%
Profit margin -90.05%
Book value $11.92
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting REGENXBIO shares

There are currently 3.3 million REGENXBIO shares held short by investors – that's known as REGENXBIO's "short interest". This figure is 5.7% up from 3.1 million last month.

There are a few different ways that this level of interest in shorting REGENXBIO shares can be evaluated.

REGENXBIO's "short interest ratio" (SIR)

REGENXBIO's "short interest ratio" (SIR) is the quantity of REGENXBIO shares currently shorted divided by the average quantity of REGENXBIO shares traded daily (recently around 561117.6369863). REGENXBIO's SIR currently stands at 5.84. In other words for every 100,000 REGENXBIO shares traded daily on the market, roughly 5840 shares are currently held short.

However REGENXBIO's short interest can also be evaluated against the total number of REGENXBIO shares, or, against the total number of tradable REGENXBIO shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case REGENXBIO's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 REGENXBIO shares in existence, roughly 80 shares are currently held short) or 0.097% of the tradable shares (for every 100,000 tradable REGENXBIO shares, roughly 97 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against REGENXBIO.

Find out more about how you can short REGENXBIO stock.

REGENXBIO share dividends

We're not expecting REGENXBIO to pay a dividend over the next 12 months.

REGENXBIO share price volatility

Over the last 12 months, REGENXBIO's shares have ranged in value from as little as $27.145 up to $50.26. A popular way to gauge a stock's volatility is its "beta".

RGNX.US volatility(beta: 1.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while REGENXBIO's is 1.0455. This would suggest that REGENXBIO's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

REGENXBIO overview

REGENXBIO Inc. , a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases.

Frequently asked questions

What percentage of REGENXBIO is owned by insiders or institutions?
Currently 12.515% of REGENXBIO shares are held by insiders and 86.671% by institutions.
How many people work for REGENXBIO?
Latest data suggests 306 work at REGENXBIO.
When does the fiscal year end for REGENXBIO?
REGENXBIO's fiscal year ends in December.
Where is REGENXBIO based?
REGENXBIO's address is: 9600 Blackwell Road, Rockville, MD, United States, 20850
What is REGENXBIO's ISIN number?
REGENXBIO's international securities identification number is: US75901B1070
What is REGENXBIO's CUSIP number?
REGENXBIO's Committee on Uniform Securities Identification Procedures number is: 75901B107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site